Senior DevOps Engineer

Certara, Inc... (4/14/26). "Press release: Thieme integrates Certara Chemaxon's new generation chemical sketcher, Marvin, into its chemical databases Science of Synthesis and Pharmaceutical Substances". Stuttgart & radnor, PA. | / | Organisation | ChemAxon Kft. | | / | Group | Certara (Group) | | / | Organisation 2 | Georg Thieme Verlag KG | | / | Group | Thieme (Group) | | / | Product | Marvin s/w | | / | / | / | Latest version of Marvin is more accurate and user-friendly for Chemical Database Subscribers Thieme Group and Certara, a global leader in model informed drug development Inc (Nasdaq: CERT) today announced the integration of Marvin with chemical databases, Science of Synthesis and Pharmaceutical Substances. Integrating the latest version of Marvin from Certara's Chemaxon portfolio makes drawing chemical structures and reactions to find matches in the databases faster, more accurate and user-friendly. Chemaxon, now part of the discovery software and services portfolio of Certara, develops cutting-edge scientific informatics software products used by the life sciences industry for research and development. Marvin, the portfolio's web-based chemical drawing software, can easily be integrated into chemical databases and other chemistry software. "Using multiple applications to draw compounds and calculate chemical properties is cumbersome and slows down scientific work. Marvin was developed as an all-in-one chemical sketcher to streamline these tasks, allowing chemists to spend less time drawing and more time driving scientific breakthroughs," said Luca Szabó, Product Manager Marvin, Chemaxon Thieme, a leading provider of information and services that contribute to the improvement of health and healthcare, is committed to delivering key information to life sciences professionals at the right time and in the right place. Discovering effective, practical experimental procedures that can be implemented quickly in the lab is central to chemists' day-to-day work. With up-to-date information, chemists can begin designing and planning syntheses immediately. A flexible, easy-to-use drawing tool with name-to-structure conversion is essential for chemical-reaction databases such as Science of Synthesis and Pharmaceutical Substances. Science of Synthesis provides full-text descriptions of organic transformations and synthetic methods as well as experimental procedures. It is a unique chemical information tool with insightful didactic reviews by experts that add real value to synthesis planning. Pharmaceutical Substances is an online tool that presents chemical structures and detailed synthetic routes, including starting materials and intermediates - for all significant APIs. All information is extracted from patent literature compiled by experienced experts in medicinal and pharmaceutical chemistry. "We were pleased with the smooth migration: no development was required for the backend, and switching the frontend from the legacy Marvin JS to the new Marvin took only minimal developer time," said Dr. Alex Russell, Product Manager Chemistry Databases at Thieme Group. "The Chemaxon team is constantly working to simplify the integration process, enabling us to provide our users with improved tools while causing minimal disruption." About Certara Chemaxon is a leading cheminformatics company that provides platforms, applications, and solutions to handle chemical entities in life sciences, biotechnology and other research industries. Certara acquired Chemaxon in 2024 to close gaps in the design-make-test-analyze cycle, bring promising leads into biosimulation, and speed up the launch of new medicines. Certara accelerates medicines using biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at certara.com About Thieme Thieme is a leading provider of information and services for the improvement of health and healthcare. With digital solutions in medicine and chemistry, Thieme supports information, communication and documentation processes in science, education, and patient care. Thieme's services are designed to be of direct benefit to their target groups - medical students, physicians, nurses, scientists, hospitals, health insurance companies, and other healthcare professionals. They receive exactly the information and services they need in a specific work situation or career. Together with a broad network of experts and partners, the digital healthcare provider ensures that it sets the pace in medical science, didactics, and technology. The family-owned company employs more than 1,000 people worldwide and is committed to improving medicine and health every day with innovative new and further developments. For more information about Thieme, please visit https://www.thieme.com. Certara Chemaxon Media Contact Alyssa Horowitz [email protected] Thieme Group Mareike Bauner [email protected] | / | / | Record changed: 2026-05-18 | More documents for Certara (Group). Find more infos about advertising at [iito] web portals in its media flyer [iito] in a Nutshell [PDF file] Please visit also its web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Cynthia Collins to leave Certara (CERT) board and Audit Committee in May 2026. Filing Impact (Moderate) Filing Sentiment Rhea-AI filing summary. Certara, Inc. reported that board member Cynthia Collins has notified the company of her intention to resign as a Class II director and member of the Audit Committee. Her resignation will be effective on May 14, 2026, the date of Certara's 2026 annual meeting of stockholders. The company states that Ms. Collins' decision to resign is not due to any disagreement with Certara regarding its operations, policies, or practices. This indicates a planned governance change rather than a dispute-driven departure. 8-K event classification. Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Key figures. Resignation effective date: May 14, 2026 Key terms. Audit Committee, Class II director, annual meeting of stockholders 03/31/2026 - 04:30 PM (Exact name of registrant as specified in its charter) (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Securities registered pursuant to Section 12(b) of the Act: On March 27, 2026, Cynthia Collins, a member of the Board of Directors (the "Board") of Certara, Inc. (the "Company") and the Audit Committee of the Board, notified the Company of her intention to resign as a Class II director on the Board, effective as of May 14, 2026, the date of the Company's 2026 annual meeting of stockholders. Ms. Collins advised the Company that her resignation is not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Faq. What board change did Certara (CERT) disclose in this Form 8-K? Certara disclosed that Cynthia Collins plans to resign as a Class II director and Audit Committee member. Her resignation is described as voluntary and not due to any disagreement over the company's operations, policies, or practices, suggesting an orderly board transition. When will Cynthia Collins' resignation from Certara's board be effective? Her resignation will be effective May 14, 2026, the date of Certara's 2026 annual meeting of stockholders. Until that date, she continues to serve as a Class II director and member of the Audit Committee under the current board structure. Did Certara (CERT) report any disagreement related to Cynthia Collins' resignation? No. Certara states that Cynthia Collins advised the company her resignation is not the result of any disagreement on operations, policies, or practices. This language is important because it signals there is no reported underlying dispute triggering her departure. What board role did Cynthia Collins hold at Certara before announcing her resignation? Cynthia Collins served as a Class II director on Certara's Board of Directors and was also a member of the Audit Committee. Her planned resignation affects both her general board seat and her oversight responsibilities on that key financial reporting committee. How does this 8-K filing affect Certara's Audit Committee composition? The filing indicates an upcoming vacancy on Certara's Audit Committee when Cynthia Collins' resignation becomes effective on May 14, 2026. The company will need to address replacement or reallocation of committee responsibilities after the 2026 annual meeting of stockholders. Filing exhibits & attachments. 3 documents